Test Code ISNP Inherited Sensory Neuropathy Gene Panel, Varies
Ordering Guidance
Targeted testing for familial variants (also called site-specific or known mutations testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.
Customization of this panel and single gene analysis for any gene present on this panel are available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.
Shipping Instructions
Specimen preferred to arrive within 96 hours of collection.
Specimen Required
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. For instructions for testing patients who have received a bone marrow transplant, call 800-533-1710.
Specimen Type: Whole blood
Container/Tube: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Any anticoagulant
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Stability Information: Ambient (preferred)/Refrigerated
Additional Information: To ensure minimum volume and concentration of DNA is met, the preferred volume of blood must be submitted. Testing may be canceled if DNA requirements are inadequate.
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file.
The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing (Spanish) (T826)
2. Molecular Genetics: Neurology Patient Information
3. If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.
Secondary ID
617597Useful For
Establishing a molecular diagnosis for patients with hereditary sensory (HSN) and autonomic neuropathy (HSAN)
Identifying variants within genes known to be associated with HSN and HSAN, allowing for predictive testing of at-risk family members
Special Instructions
Method Name
Sequence Capture and Targeted Next-Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing
Reporting Name
Sensory Neuropathy Gene PanelSpecimen Type
VariesSpecimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Varies |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
The hereditary sensory and autotomic neuropathies (HSAN), or hereditary sensory neuropathies (HSN) if autonomic dysfunction is absent, are one of the major categories of inherited peripheral neuropathies. They predominantly feature slowly progressive loss of multimodal sensation and autonomic dysfunction. The HSAN have a range of phenotypes from pure sensory involvement through phenotypes with levels of motor involvement and minor autonomic disturbances, to almost pure autonomic neuropathies. The most common features of HSAN include the loss of sensation of pain and temperature.
HSAN are subdivided into types 1 through 5 based on age of onset, inheritance pattern, and clinical features. HSAN type 1 follows an autosomal dominant inheritance pattern with juvenile through adult onset. Clinically this group is variable but can include severe sensory loss and autonomic dysfunction. HSAN type 2 follows an autosomal recessive inheritance pattern with onset in infancy or early childhood. This group is predominantly a sensory neuropathy with distal numbness and progressive loss of pain, temperature, and touch sensation. Motor involvement is not common in patients with HSAN type II. HSAN type 3 is also called familial dysautonomia and has autosomal recessive inheritance. Patients present with prominent, widespread autonomic disturbances, as well as small-fiber sensory dysfunction. HSAN type 4 is also called congenital insensitivity to pain with anhidrosis and has autosomal recessive inheritance. HSAN type 5 strongly resembles HSAN type 4, but patients show hypohidrosis instead of anhidrosis and do not have intellectual disability.
Reference Values
An interpretive report will be provided.
Interpretation
All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(1) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.
Method Description
Next-generation sequencing (NGS) and/or Sanger sequencing are performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as some other regions that have known disease-causing variants. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for deletion-insertions (delins) less than 40 base pairs (bp), above 95% for deletions up to 75 bp and insertions up to 47 bp. NGS and/or a polymerase chain reaction-based quantitative method is performed to test for the presence of deletions and duplications in the genes analyzed.
There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. See Targeted Genes and Methodology Details for the Inherited Sensory Neuropathy Gene Panel for details regarding the targeted genes analyzed for each test and specific gene regions not routinely covered.(Unpublished Mayo method)
Confirmation of select reportable variants may be performed by alternate methodologies based on internal laboratory criteria.
Genes analyzed: AIFM1, ATL1, ATL3, CLCF1, CLTCL1, COX20, CRLF1, DNMT1, DST, ELP1, GLA, KIF1A, NGF, NTRK1, PRDM12, PRKCG, RETREG1, SCN10A, SCN11A, SCN9A, SPTLC1, SPTLC2, and WNK1
Day(s) Performed
Varies
Performing Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81448
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
ISNP | Sensory Neuropathy Gene Panel | 103729-0 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
617598 | Test Description | 62364-5 |
617599 | Specimen | 31208-2 |
617600 | Source | 31208-2 |
617601 | Result Summary | 50397-9 |
617602 | Result | 82939-0 |
617603 | Interpretation | 69047-9 |
618182 | Additional Results | 82939-0 |
617604 | Resources | 99622-3 |
617605 | Additional Information | 48767-8 |
617606 | Method | 85069-3 |
617607 | Genes Analyzed | 48018-6 |
617608 | Disclaimer | 62364-5 |
617609 | Released By | 18771-6 |
Testing Algorithm
For more information see Hereditary Peripheral Neuropathy Diagnostic Algorithm